Literature DB >> 30037625

Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?

Peter Wostyn1, Debby Van Dam2, Peter Paul De Deyn3.   

Abstract

Primary open-angle glaucoma is one of the leading causes of irreversible blindness worldwide. Raised intraocular pressure is the most important modifiable risk factor and lowering it remains the mainstay therapeutic approach for slowing optic nerve damage and visual field progression in glaucoma patients. An intriguing finding of clinical retrospective and prospective studies is that intracranial pressure is lower in patients with glaucoma. Furthermore, in a recent study on monkeys subjected to an implantation of a lumboperitoneal cerebrospinal fluid shunt to lower intracranial pressure, chronic reduction in intracranial pressure was associated with the development of glaucoma-like pathology in half of the monkeys. In addition, a very recent study demonstrated that patients whose intracranial pressure has been lowered following ventriculoperitoneal shunt placement, as treatment for normal pressure hydrocephalus, have a significantly increased risk of developing normal-tension glaucoma. These findings suggest that a reduced intracranial pressure may play an important role in the pathogenesis of glaucoma. This may be due to an abnormally high pressure difference across the lamina cribrosa resulting in biomechanical changes of the optic nerve head and/or to a deficient clearance of toxic substances, particularly in the subarachnoid space of the optic nerve and/or in the 'ocular glymphatic system'. The search for drugs or medical devices useful to ameliorate glaucoma by lowering the trans-lamina cribrosa pressure difference and/or by facilitating cerebrospinal fluid circulation may therefore be an important area for future research. In this article, we propose that infusion of artificial cerebrospinal fluid through an implantable pump into the intrathecal space surrounding the spinal cord could be a new promising strategy for the treatment of glaucoma. Although the implantation of such a cerebrospinal fluid pump is a relatively invasive intervention, it seems worthwhile to make every effort to identify new therapies for patients who suffer from this devastating disease, especially given the significant number of patients for whom non-invasive treatment options are ineffective.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30037625     DOI: 10.1016/j.mehy.2018.06.026

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

1.  An ocular glymphatic clearance system removes β-amyloid from the rodent eye.

Authors:  Xiaowei Wang; Nanhong Lou; Allison Eberhardt; Yujia Yang; Peter Kusk; Qiwu Xu; Benjamin Förstera; Sisi Peng; Meng Shi; Antonio Ladrón-de-Guevara; Christine Delle; Björn Sigurdsson; Anna L R Xavier; Ali Ertürk; Richard T Libby; Lu Chen; Alexander S Thrane; Maiken Nedergaard
Journal:  Sci Transl Med       Date:  2020-03-25       Impact factor: 17.956

2.  Normal Pressure Glaucoma: The Challenge in Asia and the Scientific Contributions from Asia.

Authors:  Dennis S C Lam; Clement C Y Tham; Robert Ritch
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Nov-Dec

Review 3.  Can the Treatment of Normal-Pressure Hydrocephalus Induce Normal-Tension Glaucoma? A Narrative Review of a Current Knowledge.

Authors:  Yasin Hamarat; Laimonas Bartusis; Mantas Deimantavicius; Paulius Lucinskas; Lina Siaudvytyte; Rolandas Zakelis; Alon Harris; Sunu Mathew; Brent Siesky; Ingrida Janulevicienė; Arminas Ragauskas
Journal:  Medicina (Kaunas)       Date:  2021-03-03       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.